Skip to main content

Table 3 Cox analysis of recurrence-free survival according to HMG-CoAR protein expression in Cohort II

From: Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen

 

All tumors (n= 422)

ER-positive (n= 270)

 

Univariate

Multivariatea

Univariate

Multivariatea

 

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HMG-CoAR (0 vs. 1 to 2+)

0.68

0.51 to 0.90

0.009

0.67

0.49 to 0.91

0.01

0.66

0.46 to 0.95

0.024

0.65

0.45 to 0.96

0.029

Grade (I and II vs. III)

1.88

1.46 to 2.42

<0.001

1.58

1.11 to 2.25

0.012

1.85

1.32 to 2.60

<0.001

1.56

1.04 to 2.34

0.03

Age (continuous)

0.95

0.95 to 0.99

0.002

0.97

0.95 to 1.01

0.071

0.95

0.93 to 0.98

0.001

0.95

0.92 to 0.99

0.015

Nodal status (negative vs. positive)

1.7

1.26 to 2.29

0.001

2.12

1.47 to 3.28

<0.001

1.42

0.94 to 2.15

0.098

1.56

0.95 to 2.57

0.079

Tumor size (continuous)

1.16

0.90 to 1.50

0.254

1.27

0.91 to 1.77

0.159

1.17

0.84 to 1.64

0.361

1.22

0.81 to 1.84

0.352

ER status (0 to 10% vs. 11 to 100%)

0.71

0.54 to 0.94

0.018

0.65

0.37 to 1.13

0.126

      

PR status (0 to 10% vs. 11 to 100%)

0.73

0.54 to 0.97

0.031

1.37

0.77 to 2.43

0.285

0.94

0.832 to 1.19

0.95

2.28

0.72 to 7.27

0.163

Treatment (tamoxifen vs. control)

0.78

0.60 to 0.98

0.033

0.68

0.50 to 0.92

0.011

0.61

0.44 to 0.86

0.005

0.58

0.39 to 0.84

0.005

  1. CI, confidence interval; ER, estrogen receptor; HMG-CoAR, 3-hydroxy-3-methylglutharyl-coenzyme A reductase; HR, hazard ratio; PR, progesterone receptor. aAdjusted for all other variables in the table.